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Background/Aims: Standard approaches to trial design and analyses can be inefficient and 
non-pragmatic. Failure to consider a range of outcomes impedes evidence-based 
interpretation and reduces power. Traditional approaches synthesizing information obtained 
from separate analysis of each outcome fail to incorporate associations between outcomes 
and recognize the cumulative nature of outcomes in individual patients, suffer from 
competing risk complexities during interpretation, and since efficacy and safety analyses are 
often conducted on different populations, generalizability is unclear. Pragmatic and efficient 
approaches to trial design and analyses are needed. 
Methods: Approaches providing pragmatic assessment of benefits and harms of 
interventions, summarizing outcomes experienced by patients, and providing sample size 
efficiencies are described. Ordinal outcomes recognize finer gradations of patient responses. 
Desirability-of-outcome ranking (DOOR) is an ordinal outcome combining benefits and 
harms within patient. Analysis of DOOR can be based on rank-based methodologies 
including the DOOR probability, the win ratio, and the proportion in favor of treatment. Partial 
credit analyses, involving grading the levels of the DOOR outcome similar to an academic 
test, provides an alternative approach. The methodologies are demonstrated using the acute 
stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes 
(SOCRATES; NCT01994720), a randomized clinical trial. 
Results: Two five-level ordinal outcomes were developed for SOCRATES. The first was 
based on a Modified Rankin scale. The odds ratio is 0.86 (95% CI 0.75, 0.99; p = 0.04) 
indicating that the odds of worse stroke categorization for a trial participant assigned to 
ticagrelor is 0.86 times that of a trial participant assigned to aspirin. The 5-level DOOR 
outcome incorporated and prioritized survival; the number of strokes, myocardial infarction, 
and major bleeding events; and whether a stroke event was disabling. The DOOR probability 
and win ratio are 0.504 (95% CI 0.499, 0.508; p = 0.10) and 1.11 (95% CI 0.98, 1.26; p = 
0.10) respectively, implying that the probability of a more desirable result with ticagrelor is 
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50.4% and that a more desirable result occurs 1.11 times more frequently on ticagrelor vs. 
aspirin. 
Conclusion: Ordinal outcomes can improve efficiency though require pre-specification, 
careful construction and analyses. Greater pragmatism can be obtained by composing 
outcomes within-patient. DOOR provides a global assessment of the benefits and harms that 
more closely reflect the experience of patients. The DOOR probability, the proportion in favor 
of treatment, the win ratio, and partial credit can more optimally inform patient treatment, 
enhance the understanding of the totality of intervention effects on patients, and potentially 
provide efficiencies over standard analyses. The methods provide the infrastructure for 
incorporating patient values and estimating personalized effects.  
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Randomized clinical trials are the gold standard for evaluating the benefits and risks of 
interventions. However, these studies often fail to provide the necessary evidence to fully 
inform practical medical decision-making. The important implications of these deficiencies 
are largely absent from discourse in medical research communities.1 Contributing factors to 
these deficiencies include the over-reliance on dichotomized outcomes and the manner in 
which benefits and harms are integrated and analyzed. 
 
Outcomes in clinical trials are often dichotomized. However, dichotomized outcomes 
may fail to convey and recognize finer gradations of important patient responses. This 
potential limitation may result in reduced sensitivity and statistical power for detecting 
important effects, resulting in larger sample sizes than necessary. 
 
Typical analyses of clinical trials involve separate intervention comparisons for each of 
efficacy, safety, and quality-of-life outcomes; for example, Johnston et al, 2016.2 Outcome-
specific effects are tabulated and potentially systematically or unsystematically combined in 
benefit:risk analyses with the belief that such analyses inform of the totality of effects on 
patients. However, such approaches do not incorporate associations between outcomes of 
interest, fail to summarize the cumulative nature of different outcomes on individual patients, 
suffer from competing risk challenges when interpreting individual outcomes, and, since 
efficacy and safety analyses are frequently conducted on different analysis populations, the 
population to which these benefit:risk analyses apply, is unclear. 
 
We present and apply recently proposed methodologies for benefit:risk assessment in 
clinical trials. The methods have greater pragmatism and efficiency than traditional methods 
in that they recognize finer gradations of important patient responses and provide a global 
assessment that more closely reflects the totality of the patient experience and status. We 
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apply the methods in a post-hoc analysis of the data from SOCRATES, a large international 





Methodologies that can improve efficiency and provide greater pragmatism include use of 





Frequently utilized dichotomized outcomes may fail to elicit finer gradations of important 
responses. This approach results in reduced sensitivity and power for detecting important 
effects. Ordinal outcomes offer the opportunity to improve efficiency by recognizing finer 
gradations of patient responses. 
 
Composing outcomes within a patient 
 
Ordinal outcomes represent an incremental step to greater pragmatism. The next step is to 
appropriately compose the outcomes. Recently proposed methodologies for the evaluation 
of multiple outcomes provide the opportunity to obtain global assessments of the benefits 
and harms of interventions that more closely reflect the experience of patients. The general 
concept is based on using the outcomes to globally analyze the patient rather than using 
patient data for segmented evaluation of each outcome, and allowing for gradations in 
outcomes to be considered in assessing overall performance of an intervention through the 
use of a composite ordinal outcome. The methodologies synthesize multiple outcomes as 
they are experienced by the patients, consider the relative importance of outcomes, and 
avoid many competing risk issues that plague analyses and interpretation of single 
outcomes. 
 




Methodologies have recently been proposed to compare two treatments based on multiple 
outcomes using the concept of pairwise patient comparisons. All possible pairwise 
comparisons of the outcomes from patients in one treatment arm to the outcomes from 
patients in the other treatment arm are conducted. For example, if one treatment arm has N1 
patients and the other treatment arm has N2 patients then there are N1*N2 possible pairwise 
comparisons. When comparing a specific patient’s results from one treatment group to a 
patient from the other treatment group, a more desirable (‘win’), less desirable (‘loss’), or 
equally desirable (tie) result will be observed. 
 
One strategy for making comparisons based on multiple outcomes is via prioritization of 
outcomes.3 For example, suppose two outcomes are considered: survival and whether an 
adverse event occurred. Further, suppose that survival is prioritized over the adverse event. 
When comparing two patients, if one survived but the other did not then the patient that 
survived had the most desirable outcome. If both patients survived, they would then be 
compared with regard to their adverse event status. 
 
Comparisons can also be made by combining multiple outcomes into a single ordinal 
composite outcome. For example, the desirability of outcome ranking (DOOR) is a concept 
whereby patients are classified into an ordinal global outcome based on overall outcome 
desirability.4 The DOOR is often constructed using the major endpoints of efficacy, safety 
and quality-of-life outcomes of interest. Table 1 represents a simple example of a DOOR 
outcome using survival and adverse events. 
 
When patients have been classified then the DOOR probability (i.e. the probability of a 
more desirable result [adjusted for tied desirability]) in one treatment relative to another 
treatment, the proportion in favor of treatment,5 and the win ratio3 (i.e. the relative frequency 
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by which one treatment has a more desirable result than another) can be calculated by 
tabulating the pairwise comparison results. 
 
DOOR probability = (#wins + 0.5[#ties])/(N1*N2) 
Proportion in favor of treatment (net benefit) = (#wins – #losses)/(N1*N2) 
Win ratio = # wins/#losses 
 
The DOOR probability (similar to the Mann-Whitney probability) and the proportion in 
favor of treatment (similar to the Somers’ D[C|R]) can be viewed as absolute measures 
whereas the win ratio can be considered as a relative measure. Presentation of the absolute 
measures is recommended. Consider a comparison of two treatments for which pairwise 
comparisons result in two more desirable comparisons, one less desirable comparison, and 
97 ties resulting in a win ratio of 2. A comparison of two treatments for which pairwise 
comparisons result in two more desirable comparisons, one less desirable comparison, and 
9997 ties also results in a win ratio of 2. These two scenarios are importantly different and 
would be readily illuminated using the DOOR probability or the proportion in favor of 
treatment. 
 
Regression approaches for these methods are available to incorporate other factors, for 
example, stratification variables.6 These regression approaches have different assumptions 
compared to ordinal logistic regression but have the advantage of the ability to deal with 
censoring.7 
 
One concern with the methods based on pairwise comparisons is that a decrement in a 
very important component could be offset by a large advantage in a component outcome of 
lesser importance despite appropriate prioritization. In the case of the ordinal DOOR 
10 
 
outcome in Table 1, the step between ‘survival without adverse event’ and ‘survival with 
adverse event’ may be viewed as smaller than the step between ‘survival with adverse 





Partial credit analyses8 can be conducted to directly address the concerns with pairwise 
comparison methodologies. Partial credit analyses involve grading the levels of the ordinal 
DOOR outcome similar to an academic test, i.e. from 0% to 100%. If the patient experiences 
the most desirable overall outcome then they receive a score of 100%. If the patient has the 
least desirable result (e.g. death) then they receive a score of 0. Partial credit is given for 
intermediate categories (Table 1) directly accounting for cases in which steps between 
categories are viewed as unequal. Partial credit can be informed from patients using quality-
of-life instruments or from a survey of expert clinicians. Treatment comparisons can then be 
made by comparing mean partial credit scores. The advantage of the partial credit scoring 
approach is that it strategically scores the DOOR categories to account for non-uniform 
steps between categories. A disadvantage of the partial credit approach is that it is more 
challenging to score outcomes than to rank or prioritize them. 
 
Although partial credit scoring can be pre-specified for transparency, the treatment 
contrast can be displayed as partial credit assignment varies. This approach gives providers 
and patients the freedom to choose a treatment based on how they value the intermediate 
categories. 
 




When designing a trial with an ordinal outcome, the outcome must be clearly defined and 
pre-specified for transparency as with traditional outcomes. The calculation of sample size 
for a trial using a DOOR or other ordinal outcome can be conducted in three ways. The first 
option involves testing the null hypothesis that a patient randomly assigned to a new therapy 
will have an X% chance of a better DOOR than one assigned to the control. For X, 50% is 
often selected noting that 50% implies superiority of the new therapy to the control. Other 
values of X can be selected. The alternative hypothesis is that a patient randomly assigned 
to a new therapy will have a Y% chance of a better DOOR than one assigned to the control. 
Here Y is selected so that Y is greater than X with the improvement based upon assessment 
of clinical relevance. Using this paradigm, the required sample size can be calculated with 
standard software using the Mann-Whitney U Test when X = 50%. Simulation can be used 
with X ≠ 50%. 
 
A second, more-desirable option involves obtaining information on the proportions for the 
respective categories of the ordinal response for the two groups. The proportions in the 
categories for the control group may represent the expected responses when treated with 
the control. The proportions in the categories for the experimental group would be 
constructed by the amount of improvement in desirability that is important to detect. Once 
proportions have been identified then sample size can be calculated using standard software 
when X = 50% and simulation when X ≠ 50%.  
 
The third option involves testing the null hypothesis that the treatment-group means are 
the same when implementing a pre-specified partial credit scoring strategy. Though 
analyses can be conducted varying the scoring strategy, a specific scoring strategy can be 
pre-specified and informed by, for example, surveys of patient perspectives or treatment 
experts. Given assumed DOOR distributions for the experimental and control strategies, 
treatment-specific means and standard deviations can be obtained, and the trial can be 




Example: SOCRATES Trial 
 
The acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient 
outcomes (SOCRATES; NCT01994720) study was a multicenter, randomized, double-blind, 
double-dummy, parallel-group trial conducted at 674 sites in 33 countries between January 
7, 2014 and October 29, 2015.2,9 The objective of SOCRATES was to compare ticagrelor 
(180 mg on day 1 followed by 90 mg twice daily on days 2–90) with aspirin (300 mg on day 
1, followed by 100 mg daily on days 2–90) for the prevention of major vascular events (a 
composite of stroke, myocardial infarction [MI], or death) over a period of 90 days in patients 
with acute ischemic stroke or TIA. Eligible patients were aged 40 years, had an acute 
ischemic stroke with a National Institutes of Health Stroke Scale score of 5 or had high-risk 
transient ischemic attack (ABCD2 stroke risk score of 4 [scores assessing the risk of stroke 
on the basis of age, blood pressure, clinical features, duration of transient ischemic attack, 
and presence or absence of diabetes mellitus] or symptomatic intracranial or extracranial 
arterial stenosis), and could undergo randomization within 24 hours after symptom onset.9 
 
In SOCRATES, 13,199 patients were randomized. Demographics and baseline 
characteristics were balanced between treatment groups.2 Ticagrelor was not found to be 
superior to aspirin in reducing the rate of stroke, MI, or death at 90 days. There was a 6.7% 
event rate in the ticagrelor arm versus 7.5% rate in the aspirin arm resulting in an estimated 
hazard ratio of 0.89 (95% confidence interval [CI]: 0.78, 1.01; p = 0.07).2 PLATO major 
bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard 
ratio, 0.83; 95% CI: 0.52, 1.34) with few intracranial hemorrhages.10 
 
Traditional evaluations in cardiovascular-event prevention trials, such as SOCRATES, 
are limited to evaluating time-to-the-first event (stroke, MI, or death within 90 days). One 
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paradoxical property to such analyses is that a patient with an MI at 40 days is considered to 
be a worse outcome than a patient who dies at 60 days, as the MI occurred first and the 
focus is on the event time. This approach further ignores potentially valuable information that 
can be derived from the differential importance of the events of interest, the cumulative 
nature of multiple events, the association between events, and complexities induced by 
competing risks, for example, death informatively censoring the time to stroke. Typical 
benefit:risk assessment conducted by separately estimating an effect for each important 
outcome, for example, death, MI, stroke, and bleeding, and then combining the effects on 
these outcomes in some way, is difficult to interpret. Since these events are not mutually 
exclusive (e.g. fatal bleeding event), events can be double-counted.11 Ordinal outcome and 







Separate ordinal outcomes 
 
The results of the SOCRATES trial for an ordinal outcome based on a Modified Rankin scale 
using ordinal logistic regression analyses12,13 are shown in Table 2. Advantages of this 
approach are: (1) recognition of important finer gradations of patient response, more closely 
reflecting the differential impact of therapies and (2) greater sensitivity providing efficiencies. 
 
The results of the efficacy stroke analyses suggest that ticagrelor is superior to aspirin 
(odds ratio = 0.862; 95% CI 0.747, 0.995; p = 0.04) indicating that the odds of worse stroke 
categorization for a trial participant assigned to ticagrelor is 0.862 times that of a trial 
participant assigned to aspirin. These results are similar to the time-todichotomized all- 
stroke analyses (estimated hazard ratio of 0.86; 95% CI 0.75, 0.00; p = 0.03) and the 
dichotomized primary endpoint i.e. the time-to event analyses of the composite of stroke, MI, 
or death (estimated hazard ratio of 0.89 [95% CI 0.78, 1.01; p = 0.07]).2 
 
The results of the safety analyses of hemorrhage suggest a significant increase in 
bleeding for ticagrelor versus aspirin (p0.0001), a result mainly driven by no event vs. any 
event analyses. These though analyses are difficult to interpret , mainly driven by no event 
versus any event since there are low percentages for the three most severe types of events 
and aspirin had more PLATO major bleeding events. Given the tradeoff of efficacy and 
safety, careful synthesis of these evaluations through benefit:risk evaluation is required.  
 
Limitations of the separate ordinal outcome analyses approach include: (1) MIs are not 
included; (2) ordinal logistic regression requires that the proportional odds assumption hold 
to ensure validity and has difficulty dealing with censoring; (3) difficulty synthesizing separate 
relative measures for efficacy and safety, for example, an odds ratio of 2 could imply 
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increase of risk of 1 in 10 to 2 in 10 indicating a high level of importance, or alternatively 
imply an increase of risk from 1 in 10,000 to 2 in 10,000 representing a much lower level of 
importance; (4) associations between efficacy and safety not evaluated; and (5) the efficacy 




DOOR analyses were conducted building upon the advantages of the ordinal outcome. 
DOOR addresses the limitations of the separate ordinal outcome evaluation described 
above by: (1) including MIs; (2) using the DOOR probability and win ratio, which do not 
require the proportional odds assumption; (3) focusing on a composed absolute measure 
(i.e. DOOR probability); (4) examining the association between the various component 
outcomes by synthesizing the benefits and harms within patient, and (5) conducting 
harmonized analyses on a single analysis population (intent-to-treat).  
 
DOOR was constructed as a global composite ordinal outcome incorporating major 
events (death, stroke, MI, and major bleeding). Construction of the DOOR prioritized death 
over non-fatal events, disabling over non-disabling events, and more events over fewer 
events. The DOOR consisted of five levels (from most to least desirable): (1) survived with 
no event, (2) survived with non-disabling stroke, MI, or PLATO-defined major bleeding (one 
event), (3) survived with non-disabling stroke, MI, or PLATO-defined major bleeding (1 
event), (4) survived with disabling stroke, and (5) death. The distribution of patients was 
92.9%, 2.2%, 0.1%, 3.7%, and 1.0% for ticagrelor, and 92.1%, 2.6%, 0.2%, 4.3%, and 0.9% 
for aspirin in categories 1–5, respectively (Table 3). The cumulative difference (ticagrelor – 
aspirin) in proportions can be evaluated by sequentially dichotomizing the DOOR outcome. 
For example, one can dichotomize ‘survived with no event’ versus other categories resulting 
in difference of 0.8% (95% CI –0.1, 1.7). At the other extreme, one can dichotomize the last 
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category (death) versus other categories yielding an analysis of survival resulting in a 
difference of –0.2% (95% CI –0.5, 0.2). 
The DOOR probability is 0.504 (95% CI 0.499, 0.508; p = 0.096) implying that the 
probability of a more desirable result with ticagrelor is 50.4%. The win ratio = 1.11 (95% CI 
0.98, 1.26; p = 0.096), implying that a more desirable result occurs 1.11 more frequently on 




To illustrate partial credit analyses, we collapse categories 2 and 3 so that there are four 
total categories i.e. (1) survived with no event, (2) survived with non-disabling event(s), (3) 
survived with disabling stroke, and (4) death. Partial credit (between 0 and 100%) is 
provided to the two middle categories with partial credit for surviving with a non-disabling 
event (p1) greater than that for surviving with a disabling stroke (p2). Contours of the 
difference (ticagrelor – aspirin) in mean partial credit scores (Figure 1A) and ratio 
(ticagrelor/aspirin) of partial credit scores (Figure 1B) can be plotted for varying values of p1 
and p2 to evaluate the robustness of the results and to allow for personalized choices 
regarding the values of p1 and p2. 
 
If partial credit of 100% is given to categories (2) and (3) (Figure 1A, point C), equivalent 
to analysis of survival, then the difference in means is –0.15 (95% CI –0.49, 0.18). If a partial 
credit of 0% is given to these two categories (Figure 1A, point A), equivalent to analysis of 
zero versus any event, then the difference in means is 0.82 (95% CI –0.07, 1.72). Quality-of-
life studies can be used to provide patient or clinician perspectives to better inform partial 
credit scoring. Using partial credit scoring of 68 for a non-disabling event and 38 for a 
disabling event (scoring derived from Okumura et al, 2015)14 (Figure 1A, point E), the 
difference in means is 0.32 (95% CI –0.22, 0.87). Table 4 summarizes the partial credit 
analyses. Analysis for any other scoring strategy can also be evaluated noting that patients 
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have their own values and that patients’ perspectives can vary from that of clinicians.15 
Results for the ratio of scores are also provided in Figure 1B and Table 4. 
 
Subgroup evaluation for personalized medicine 
 
Since benefits and harms have been synthesized by composing them within patients, 
subgroup evaluations can be conducted to evaluate how the global effects of therapy may 
vary by patient characteristics. We examined the ticagrelor – aspirin comparison by 
subgroups defined by: (1) whether the patient had prior aspirin use, and (2) the time-to-
loading dose. Results suggest that the advantages with ticagrelor are for patients with prior 
aspirin and shorter times to the loading dose (Table 5). Such analyses, more appropriately 
convey the heterogeneity of effects on patients compared with subgroup analyses based on 







Dichotomized outcomes provide simplicity at the expense of inefficiencies, thereby possibly 
resulting in the failure to recognize finer but important gradations of patient responses. 
Ordinal outcomes may improve efficiencies though require careful construction, pre-
specification, and analyses. 
 
DOOR is a composite ordinal outcome that provides the opportunity to obtain global 
assessments of the benefits and harms of interventions that more closely reflect the 
experience of patients. Rank-based methods (the DOOR probability, the proportion in favor 
of treatment, and the win ratio) and a score-based method, partial credit are available to 
compare the DOOR outcome between interventions to more optimally inform patient 
treatment by enhancing the understanding of the totality of intervention effects on patients. 
Critical components include: (1) using outcomes to analyze patients rather than using 
patients to analyze outcomes, (2) incorporating patient values, and (3) evaluating 
personalized effects. A critical factor in this approach requires improved understanding of 
how to analyze one patient before analyzing many patients. 
 
Construction of DOOR and other composite outcomes is challenging, requiring great 
care to ensure the composition appropriately recognizes the relative importance of individual 
outcomes.16 The importance of recognizing the differential impact of events of interest has 
been noted. For example, in weighing the risks and benefits of prasugrel for the reduction of 
thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina 
or MI) who undergo percutaneous coronary intervention, the Food and Drug Administration 
(FDA) review team noted that the components of the primary endpoint (death, MI, stroke) 
represented irreversible tissue damage. They concluded that the benefit of preventing such 
events is generally worth the risk of bleeding events that are generally transient and have no 
irreversible consequences. Bleeding events may have serious consequences, but most of 
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those that led to irreversible harm (e.g. intracranial hemorrhage) were included in the 
primary endpoint.17 Similarly, during the evaluation of dabigatran for the reduction of the risk 
of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, the FDA 
described why they approved a higher dose rather than a lower dose. The FDA again noted 
that nonfatal and extracranial bleeding episodes are less clinically significant than strokes for 
most patients, as the irreversible effects of strokes and systemic emboli have greater clinical 
significance than nonfatal bleeding. They concluded that benefit:risk assessment in which 
strokes and systemic emboli are given more weight than non-fatal bleeding events results in 
the higher dabigatran dose being more favorable.18  
 
The SOCRATES trial was used as an example to illustrate application of the 
methodologies. DOOR was constructed using death, stroke, MI, and PLATO-defined major 
bleeding events. The construction attempted to recognize that: (i) fatal events are worse 
than non-fatal events, (ii) disabling events are worse than non-disabling events, and (iii) 
multiple events are worse than fewer events. Elements of this construction can be 
questioned. For example, some data suggests that patients view certain strokes (i.e. 
mRS=5) as worse than death.19 Others may question the assumption of equal importance of 
MIs, non-disabling strokes and major bleeds. Non-disabling stroke is moderately 
homogeneous in severity and effect on patient function but MIs and major bleeds have more 
variable sequelae. Alternative constructions of DOOR could be pursued shaped by studies 
that evaluate the importance of component outcomes.20,21 Additional categories could be 
constructed to recognize the heterogeneous nature of the effects of MIs and bleeds. Co-
morbidities such as pulmonary embolism and aspiration pneumonia could be integrated. 
Utilization of levels of the ordinal Modified Rankin scale may provide greater sensitivity.  
 
Application of the new methodologies does not mitigate the necessity of the evaluation of 
component outcomes. Analyses of component outcomes provide value and should be 
considered part of the application of the new methodologies. For example, analyses of 
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safety outcomes may uncover toxicity that may be reduced by modification of the dose or 
delivery system. 
 
Although we have discussed the methodologies within the context of the SOCRATES 
trial focused on whether ticagrelor prevents short-term (within 90 days) cardiovascular 
events, application of the methodologies can be modified and tailored to trials for which the 
event time is important to consider. For example, a long-term trial evaluating survival time 
may categorize survival duration with long-term survival being more desirable than short-
term survival. The methods are being tailored and employed in other disease settings such 
as infectious disease22‒24 and oncology.25 The methods have recently been proposed as a 
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Table 1. Example of Desirability-of-Outcome Rankings (DOOR). 
DOOR Category Partial Credit Scoring 
Survival without adverse event (most desirable) 100% 
Survival with adverse event Partial credit 





Table 2. Ordinal outcome analyses for efficacy and safety in the SOCRATES trial. 
Analysis Category Ticagrelor 
(N = 6589) 
n (%) 
Aspirin 
(N = 6610) 
n (%) 
OR (95% CI)a p-value 
Efficacy 
Strokeb,c 
   0.862  
(0.747–0.995) 
0.0419d 
 Stroke mRS 6e 33 (0.5) 26 (0.4)   
 Stroke mRS 4–5 65 (1.0) 86 (1.3)   
 Stroke mRS 2–3 144 (2.2) 152 (2.3)   
 Stroke mRS 0–1 131 (2.0) 167 (2.5)   
 No event 6199 (94.3) 6160 (93.5)   
Bleeding 
(safety)f 
PLATO major Fatal 
 
9 (0.1) 4 (0.1)  0.0001g 
 PLATO major Life-
threatening 
13 (0.2) 23 (0.3)   
 PLATO major Other 9 (0.1) 11 (0.2)   
 PLATO minor 75 (1.1) 44 (0.7)   
 PLATO minimal 499 (7.6) 234 (3.6)   
 No event 5944 (90.8) 6265 (95.2)   
aOdds ratio analyses were not performed for safety given a violation of the proportional odds 
assumption; bFull analysis set; cPatients with stroke with a missing mRS were excluded; dWald test; 
emRS = 6 includes deaths due to reasons unrelated to stroke; fSafety analysis set including events on 
or after the date of first dose up to 7 days after the date of last dose; gWilcoxon test. 
CI: confidence interval; mRS: modified Rankin Scale; OR: odds ratio; PLATO: Platelet Inhibition and 




Table 3. DOOR and component outcomes by treatment. 
 
Ticagrelor  
(N = 6589)  
n (%)  
Aspirin  
(N = 6610)  
n (%)  
Cumulative difference  
% (95% CI)  
DOORa,b    
  Survived with no event  6124 (92.9)  6089 (92.1)  0.8 (–0.1, 1.7)  
  Survived with non-disabling stroke, MI 
or PLATO major bleeding, 1 event  
147 (2.2)  171 (2.6)  0.5 (–0.3, 1.2)  
  Survived with non-disabling stroke, MI 
or PLATO major bleeding, 1 event  
6 (0.1)  11 (0.2)  0.4 (–0.3, 1.1)  
  Survived with disabling stroke  244 (3.7)  281 (4.3)  –0.2 (–0.5, 0.2)  
  Death  68 (1.0)  58 (0.9)   
Component Outcomes    
  MI 25 (0.4) 21 (0.3)  
  PLATO major bleeding 45 (0.7) 44 (0.7)  
  Non-disabling stroke 113 (1.7) 143 (2.2)  
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  Disabling stroke 277 (4.2) 307 (4.6)  
aPatients with stroke but missing mRS were characterized as disabling strokes; bIntention-to-treat analysis set.  














Figure 1A &1B 
Depiction 
Difference in 
means and 95% CI 
(Ticagrelor – 
aspirin)  
Ratio and 95% CI 
(Ticagrelor/aspirin) 
























Table 5. Subgroup analyses from the SOCRATES trial. 






(n = 68) and 
disabling stroke 
(n = 38) 
Ticagrelor:aspirin 
ratio and 95% CI 






































aA win ratio greater than one and a DOOR probability greater than 0.5 favors ticagrelor 
bTreatment x prior aspirin interaction test p-value = 0.337 
cTreatment x time to loading dose interaction test p-value = 0.096  




Figure 1. A) Contours of the difference (ticagrelor – aspirin) in mean partial credit scores as 
a function of the partial credit provided for survival with a non-disabling event (y-axis) and 
survival with a disabling event (x-axis). A difference of zero indicates equivalence. 
B) Contours of the ratio (ticagrelor/aspirin) in partial credit scores as a function of the partial 
credit provided for survival with a non-disabling event (y-axis) and survival with a disabling 
event (x-axis). A ratio of 1 represents equivalence. 
 
 
